Spice drugs: cannabinoids as a new designer drugs

被引:37
作者
Mustata, Cristina [1 ,2 ]
Torrens, Marta [1 ,3 ]
Pardo, Ricardo [1 ,2 ]
Perez, Clara [1 ,2 ]
Farre, Magi [1 ,2 ]
机构
[1] Hosp del Mar, IMIM, Unidad Farmacol Humana & Neurociencias, Programa Neuropsicofarmacol, Barcelona 08003, Spain
[2] Univ Autonoma Barcelona, Barcelona, Spain
[3] Hosp del Mar, IMIM, Unidad Toxicomanias, Inst Atencio Psiquiatr Salut Mental & Toxicomanie, Barcelona 08003, Spain
关键词
Spice drugs; synthetic cannabinoids designer drugs; JWH-018; CP; 47497; JWH-073; HU-210; RECEPTORS; CB1; CLASSIFICATION; PHARMACOLOGY; ANANDAMIDE; AGONISTS;
D O I
10.20882/adicciones.227
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Some smokable herbal mixtures under the brand name Spice drugs have been sold on the Internet and in specialised shops (smart shops) since 2004. The mixtures are advertised as an exotic incense blend which releases a rich aroma and not for human consumption. When smoked, Spice drugs products have been reported by some users to have effects similar to those of cannabis. Spice drugs have received intensive attention in drug forums due to the possibility to obtain a non legal substitute of cannabis. Forensic analyses have found different potent synthetic cannabinoid agonists in some Spice drugs products, as JWH-018, CP 47497, JWH-073 and HU-210. There are few data about its pharmacological properties in animals, but nothing about its toxicity. At present, almost nothing is known about the pharmacology, toxicology and safety profile of such compounds in humans, except the opinions of consumers in internet forums. Neither the herbal ingredients of Spice drugs, nor any of the synthetic cannabinoids found in them, are internationally controlled under the 1961 or 1971 UN drug control conventions. Some European countries have recently taken legal actions to ban or otherwise control Spice drugs products and related compounds. These cannabinoid substances can be considered as new products to be added to the list of "designer drugs".
引用
收藏
页码:181 / 186
页数:6
相关论文
共 22 条
[1]   Cannabinoids in medicine: A review of their therapeutic potential [J].
Amar, MB .
JOURNAL OF ETHNOPHARMACOLOGY, 2006, 105 (1-2) :1-25
[2]   Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective Agonists [J].
Ashton, John C. ;
Wright, Jason L. ;
McPartland, John M. ;
Tyndall, Joel D. A. .
CURRENT MEDICINAL CHEMISTRY, 2008, 15 (14) :1428-1443
[3]   Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding [J].
Aung, MM ;
Griffin, G ;
Huffman, JW ;
Wu, MJ ;
Keel, C ;
Yang, B ;
Showalter, VM ;
Abood, ME ;
Martin, BR .
DRUG AND ALCOHOL DEPENDENCE, 2000, 60 (02) :133-140
[4]   'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? [J].
Auwaerter, Volker ;
Dresen, Sebastian ;
Weinmann, Wolfgang ;
Mueller, Michael ;
Puetz, Michael ;
Ferreiros, Nerea .
JOURNAL OF MASS SPECTROMETRY, 2009, 44 (05) :832-837
[5]  
BUCHANAN JF, 1988, MED TOXICOL ADV DRUG, V3, P1
[6]  
COMPTON DR, 1992, J PHARMACOL EXP THER, V260, P201
[7]  
*EUR MON CTR DRUGS, 2009, EMCDDA EXP M 6 MAR L
[8]   International Union of Pharmacology. XXVII. Classification of cannabinoid receptors [J].
Howlett, AC ;
Barth, F ;
Bonner, TI ;
Cabral, G ;
Casellas, P ;
Devane, WA ;
Felder, CC ;
Herkenham, M ;
Mackie, K ;
Martin, BR ;
Mechoulam, R ;
Pertwee, RG .
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) :161-202
[9]   Synthesis and pharmacology of the 1'2'-dimethylheptyl-Delta(8)-THC isomers: Exceptionally potent cannabinoids [J].
Huffman, JW ;
Duncan, SG ;
Wiley, JL ;
Martin, BR .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (21) :2799-2804
[10]  
JARBE TUC, 1989, J PHARMACOL EXP THER, V250, P1000